SCHEMBL3216249

SCHEMBL3216249

OCc1cc(C2CC2)nn1Cc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.58
KCNJ6 P48051 3/20 0.43
KCNJ5 P48544 3/20 0.43
KCNJ3 P48549 3/20 0.43
FAAH O00519 1/20 0.36
P2RX7 Q99572 2/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
FFAR4 Q5NUL3 1/20 0.36
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
CCR2 P41597 1/20 0.35
CRHR1 P34998 1/20 0.35
CRHR2 Q13324 1/20 0.35
KDM4E B2RXH2 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3198446 0.85 PPARG (0.67) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL4613947 0.82 PPARG (0.54) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL27716301 0.81 PPARG (0.58) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL3210877 0.81 PPARG (0.59) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL3205336 0.80 PPARG (0.57) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL3212661 0.79 NPC1 (0.49) PPARGPTGDR2GABRA2GABRB2CCR2
SCHEMBL3206852 0.79 PPARG (0.67) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL3206869 0.79 PPARG (0.67) PPARGKCNJ6KCNJ5KCNJ3FAAH
SCHEMBL3221727 0.77 PPARG (0.54) PPARGKCNJ6KCNJ5KCNJ3PTGDR2
SCHEMBL3198995 0.75 PPARG (0.81) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885KCNJ6 3589/4885KCNJ5 3431/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 PPARG 30/4885KCNJ6 3134/4885KCNJ5 2900/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 PPARG 31/4885KCNJ6 3589/4885KCNJ5 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.